Tyroservatide

Drug Profile

Tyroservatide

Alternative Names: CMS-024-02

Latest Information Update: 08 Jan 2016

Price : $50

At a glance

  • Originator China Medical System; Shenzhen Kangzhe Pharmaceutical
  • Developer Shenzhen Kangzhe Pharmaceutical
  • Class Antineoplastics; Oligopeptides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 31 Mar 2007 CMS files an application for approval of a phase II trial with China's State FDA for non-small lung cancer
  • 30 Nov 2006 CMS completes a phase I trial in non-small cell lung cancer in China
  • 31 Mar 2006 Phase-I clinical trials in Non-small cell lung cancer in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top